Where does Sarepta Therapeutics, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Sarepta Therapeutics, Inc. ranks #3,545 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Sarepta Therapeutics, Inc. hold?

Sarepta Therapeutics, Inc. holds 104 US utility patents granted between 2015 and 2025, spanning 16 technology areas.

What is Sarepta Therapeutics, Inc.'s Innovation Score?

Sarepta Therapeutics, Inc. has an Innovation Score of 46.1 out of 100 (top 22% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Sarepta Therapeutics, Inc.'s patent grant rate increasing or decreasing?

Sarepta Therapeutics, Inc.'s recent grant velocity is +6% compared to the prior five-year period (grant years, not application filing dates). The company is maintaining or growing its granted-patent output.

What does claim depth mean for Sarepta Therapeutics, Inc.'s patents?

Sarepta Therapeutics, Inc.'s patents average 18.7 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Sarepta Therapeutics, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Sarepta Therapeutics, Inc.

Q: What technology areas does Sarepta Therapeutics, Inc. focus on?

Sarepta Therapeutics, Inc.'s top technology area is C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media) with 93 patents, ranking #98 of 4,144 assignees active in that subclass. Grants appear in 16 CPC subclasses total.

USPTO PatentsView assignee record - 104 granted patents across 16 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Sarepta ranks #3,545 of 49,997 tracked US assignees by granted-patent volume, with 104 patents across 16 technology areas.

#3,545
of 49,997 US assignees by volume: Top 22%
by Innovation Score (46.1/100): 18.7
avg claims per patent: +6%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R3545 · US Corporation #3,545 · 104 grants

GRANTS-MID · TOP-DECILE · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · VEL-FLAT · BOOK-FULL

GRANTS-MID 104 grants
TOP-DECILE #3,545/49,997
PHOTO-FINISH Sakata Seed
CPC-FOCUS C12N · 16 areas
INNOV-PAR 46.1/100
CLAIMS-RICH 18.7 claims/avg
TYPE-USCORP US Corporation
VEL-FLAT +6% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Sakata Seed Corporation (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Sarepta’s 46.1 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 16.1 pts (35%) Velocity 4.7 pts (10%) Breadth 14.1 pts (31%) Claim depth 11.2 pts (24%)

Qualcomm Incorporated · highest

85
Fuji Machine MFG · near

46
Infinity Pharmaceuti… · near

46
Leeb Innovations · near

46
OMS Investments · near

46
Sarepta Therapeutics · this assignee

46
3D Lighting… · lowest

7

What this shows Sarepta's Innovation Score is 46.1/100 (top 22% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Sarepta?

Each dot is one of Sarepta’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Sarepta’s own 18.7 claims/patent is ABOVE the 16.1 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Sarepta vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Sarepta's grants concentrate

Sarepta Therapeutics, Inc. is a focused PatentsView assignee: 16 CPC subclasses with 89.4% of grants classified under C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media). Peak complete grant year is 2016 (18 grants) versus a trough of 4 in 2017. By volume, Sarepta sits between Stamicarbon B.V. and Weka.IO Ltd..

Sarepta's three-year grant acceleration

From 2019–2021 to 2022–2024, Sarepta Therapeutics, Inc. moved from 34 to 24 grants (0.71x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #2,135. See the growth leaderboard.

Stamicarbon B V

104
Sunonwealth Elect…

104
Synamedia

104
Sakata Seed

104
Sensel

104
Skorpios

104
Video Gaming

104
Weka IO

104
Sarepta Therapeut… ◀

104

What this shows Sarepta holds 104 patents at rank #3,550, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Sarepta

By rank, the assignees closest to #3,550 in granted patent volume.

Leaders in C12N (Microorganisms OR Enzymes)

Other assignees with the most granted patents in Sarepta's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Sarepta, neither rank-band nor same-CPC leaders (those blocks stay above). In C12N (Microorganisms OR Enzymes), Sarepta ranks #98 of 4,144 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (46 here).

OMS Investments, Inc. 46 Infinity Pharmaceuticals, Inc. 46 Leeb Innovations, LLC 46 Fuji Machine MFG. Co., Ltd. 46

Similar claim depth

Nearest assignees by average claims per patent (18.7 here).

Lattice Semiconductor Corporation 18.7 avg Great Lakes NeuroTechnologies Inc. 18.7 avg Eyelock LLC 18.7 avg American Express Travel Related Services Company, Inc. 18.7 avg

Sarepta's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

46 Top 22% higher than 78% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Sarepta Therapeutics, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	6	5.8%
2016	18	17.3%
2017	4	3.8%
2018	11	10.6%
2019	8	7.7%
2020	11	10.6%
2021	15	14.4%
2022	10	9.6%
2023	6	5.8%
2024	8	7.7%
2025partial year	7	6.7%

Which technologies does Sarepta Therapeutics, Inc. patent most?

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 93

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 83

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 63

C07K - Peptides 25

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 24

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 16

Y02A - Technologies FOR Adaptation TO Climate Change 11

C07D - Heterocyclic Compounds 7

Y02P - Climate Change Mitigation Technologies IN THE Production OR Processing OF Goods 5

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 4

C12Y - Enzymes 3

C08F - Macromolecular Compounds Obtained BY Reactions Only Involving Carbon-to-carbon Unsaturated Bonds 3

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 3

A01K - Animal HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; Rearing OR Breeding Animals, NOT Otherwise Provided FOR; NEW Breeds OF Animals 3

Y10T - Technical Subjects Covered BY Former US Classification 2

Top 15 of 16 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Sarepta Therapeutics, Inc.'s patent record in context - here's where to go next.

Sarepta Therapeutics, Inc.'s lead technology class is C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media), 89.4% of its portfolio - see every assignee active in that class. Explore C12N
Ranked #3,545 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Sarepta Therapeutics, Inc. against Stamicarbon B.V., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 46.1/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.